Menu
GeneBe

rs5030818

Variant summary

Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong

The NM_000551.4(VHL):c.481C>G(p.Arg161Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R161Q) has been classified as Pathogenic.

Frequency

Genomes: not found (cov: 32)

Consequence

VHL
NM_000551.4 missense

Scores

9
7
2

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:3

Conservation

PhyloP100: 1.16
Variant links:
Genes affected
VHL (HGNC:12687): (von Hippel-Lindau tumor suppressor) This gene encodes a component of a ubiquitination complex. The encoded protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. In addition to oxygen-related gene expression, this protein plays a role in many other cellular processes including cilia formation, cytokine signaling, regulation of senescence, and formation of the extracellular matrix. Variants of this gene are associated with von Hippel-Lindau syndrome, pheochromocytoma, erythrocytosis, renal cell carcinoma, and cerebellar hemangioblastoma. [provided by RefSeq, Jun 2022]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 18 ACMG points.

PM1
In a hotspot region, there are 15 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 9 uncertain in NM_000551.4
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr3-10149805-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 182983.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.991
PP5
Variant 3-10149804-C-G is Pathogenic according to our data. Variant chr3-10149804-C-G is described in ClinVar as [Pathogenic]. Clinvar id is 618484.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
VHLNM_000551.4 linkuse as main transcriptc.481C>G p.Arg161Gly missense_variant 3/3 ENST00000256474.3
VHLNM_198156.3 linkuse as main transcriptc.358C>G p.Arg120Gly missense_variant 2/2
VHLNM_001354723.2 linkuse as main transcriptc.*35C>G 3_prime_UTR_variant 3/3
VHLNR_176335.1 linkuse as main transcriptn.810C>G non_coding_transcript_exon_variant 4/4

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
VHLENST00000256474.3 linkuse as main transcriptc.481C>G p.Arg161Gly missense_variant 3/31 NM_000551.4 P1P40337-1

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
Cov.:
30
GnomAD4 genome
Cov.:
32

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingInvitaeJul 14, 2022For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg161 amino acid residue in VHL. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12000816, 14767570, 20120764, 23842656, 25371412). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt VHL protein function. ClinVar contains an entry for this variant (Variation ID: 618484). This missense change has been observed in individuals with clinical features of von Hippel-Lindau syndrome (PMID: 8707293, 10567493, 19464396, 23512077). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 161 of the VHL protein (p.Arg161Gly). -
not provided Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesNov 03, 2017- -
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsAug 03, 2020The p.R161G pathogenic mutation (also known as c.481C>G), located in coding exon 3 of the VHL gene, results from a C to G substitution at nucleotide position 481. The arginine at codon 161 is replaced by glycine, an amino acid with dissimilar properties. This mutation has been identified in multiple individuals and families with histories consistent with Von Hippel-Lindau syndrome (Glavac D et al. Hum. Genet., 1996 Sep;98:271-80; Gläsker S et al. J. Neurol. Neurosurg. Psychiatry, 1999 Dec;67:758-62; Murgia A et al. Hum. Mutat., 2000 Jan;15:114; Ciotti P et al. Eur J Med Genet 2009 May;52:311-4; Kim HJ et al. Laryngoscope, 2013 Feb;123:477-83; Fishbein L et al. Ann. Surg. Oncol., 2013 May;20:1444-50; Krauss T et al. Endocr. Relat. Cancer, 2018 09;25:783-793). One study predicted this alteration to be pathogenic using a Bayesian model that incorporates phylogenetic, biochemical, and structural features (Cai Z et al. Hum. Mutat., 2004 Aug;24:178-84). In another study, in vitro experiments suggest that mutations affecting residue 161, such as p.R161G, negatively impact elongin-binding activity (Ohh M et al. J. Clin. Invest., 1999 Dec;104:1583-91). Of note, this alteration is also designated as 694C>G in the published literature. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.97
BayesDel_addAF
Pathogenic
0.51
D
BayesDel_noAF
Pathogenic
0.49
Cadd
Uncertain
26
Dann
Uncertain
1.0
DEOGEN2
Pathogenic
0.99
D;.
Eigen
Uncertain
0.24
Eigen_PC
Benign
0.17
FATHMM_MKL
Uncertain
0.77
D
LIST_S2
Uncertain
0.91
D;D
M_CAP
Pathogenic
0.83
D
MetaRNN
Pathogenic
0.99
D;D
MetaSVM
Pathogenic
1.0
D
MutationAssessor
Uncertain
2.4
M;.
MutationTaster
Benign
1.0
D;D
PrimateAI
Uncertain
0.75
T
PROVEAN
Pathogenic
-4.6
D;D
REVEL
Pathogenic
0.83
Sift4G
Uncertain
0.016
D;D
Polyphen
1.0
D;D
Vest4
0.94
MutPred
0.96
Loss of helix (P = 0.0072);.;
MVP
1.0
MPC
1.2
ClinPred
1.0
D
GERP RS
2.9
Varity_R
0.99
gMVP
0.93

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs5030818; hg19: chr3-10191488; COSMIC: COSV56564848; API